Copenhagen - Oct 29, 2021 - Mangold Fondkommission AB issued today an updated Equity Analyst Report on 2cureX (Insight.Mangold (https://mangold.se/bolag/2curex/)).

The report is in Swedish at 2cureX's web-site (Analyst Coverage).

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first IndiTreat test is aimed at optimizing treatment decisions in patients with metastatic colorectal cancer facing their third line of therapy. Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se

ProInvestor.com modtager betaling fra 2cureX for digital IR.

98161_2curex_update_2021_10_29.pdf